Companies Dominating the Opioid Antagonist Landscape
- Indivior PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- •Regional Presence
- SWOT Analysis
- Alkermes.
- Titan Pharmaceuticals, Inc.
- Hikma Pharmaceuticals PLC
- Orexo AB
- Camurus AB
- Acura Pharmaceuticals.
- Collegium Pharmaceutical
- AstraZeneca
- Viatris Inc.
- Catalent, Inc
Browse Key Market Insights with Data Illustration:
In the News
- A commercial supply agreement has been signed by Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making affordable naloxone available to everyone, and Catalent, the global leader in enabling the development and supply of better treatments for patients. As per the agreement, Catalent will produce RiViveTM (3.0 mg) naloxone nasal spray from Harm Reduction Therapeutics for the urgent treatment of confirmed or suspected opioid overdoses.
- The U.S. Food and Drug Administration ("FDA") has approved Titan Pharmaceuticals, Inc.'s application for an Investigational New Drug ("IND") study of its subdermal formulation of nalmefene, an opioid antagonist, for up to six months or longer. The purpose of the formulation is to prevent relapse in adults with opioid use disorder ("OUD") after they have completed opioid detoxification.